PRDX6 knockdown sensitizes multiple myeloma cells to ferroptosis through inactivation of the PI3K/AKT pathway. (PubMed, Expert Rev Hematol) - Apr 11, 2025 - "MM cells were treated with pLKO-shPRDX6 vectors expressing PRDX6 shRNA alone or in combination with Erastin/ferrostatin-1 (ferroptosis activator/inhibitor) or 740Y-P (PI3K/AKT pathway activator)...Furthermore, PRDX6 knockdown lowered the levels of PI3K/AKT pathway-associated molecules (p < 0.05). PRDX6 knockdown may exert pro-ferroptotic effects through inactivation of the PI3K/AKT pathway, underlying an appealing therapeutic target for MM."
Journal • Hematological Malignancies • Multiple Myeloma • Oncology • GPX4 • PRDX6 • SLC7A11
|
|
Guifang Hu; HongJu Zhang; Jingfeng Lu; Ke Dong; Wu Gao; Yun Wang
|